prevent various chronic diseases [13] [14] [15] . Pycnogenol has numerous beneficial properties, including antiinflammatory, antioxidant, and anti-obesity activities [16] [17] [18] . Pycnogenol supplementation, in particular, inhibits adipocyte differentiation and stimulates selective lipolysis in small lipid droplets within differentiated 3T3-L1 cells [19, 20] . Its anti-obesity effects, including increased levels of lipase and decreased levels of the enzyme that regulate hepatic de novo lipogenesis, were also demonstrated in ob/ob mice [21] .
PineXol (Nutrapharm Co., Korea), extracted from the bark of Korean red pine (Pinus densiflora), has been reported to have similar beneficial effects, including antioxidant, antiinflammatory, and antilipogenic activities in vitro [22, 23] . The composition of PineXol is similar to that of Pycnogenol, with comparable phenolic compounds (catechin and taxifolin) and flavonoids (procyanidin B1 and B2), according to HPLC analyses [24, 25] . However, the anti-obesity effects of PineXol in vivo have not yet been studied. The current study tested the hypothesis that PineXol supplementation would have anti-obesity effects mediated by a reduction in de novo lipogenesis and adipogenesis in mice fed a highfat diet (HFD).
Materials and Methods

Animals and Diets
The use of animals followed the protocol approved by IACUC at Kookmin University (KMU-2015-2). Four-week-old male C57BL/6 mice were purchased from Dae-han Bio Link (Korea). The animal facility was maintained at 22 ± 1°C and 50 ± 10% relative humidity, with a 12-h light (7 am to 7 pm)/dark cycle. Four mice were placed in each individually ventilated cage. Animals were adapted to the environment for 1 week prior to experimentation. Mice were fed either normal chow (2018S; Harlan, Switzerland) or a HFD (D12492; Research Diets, Inc., USA). The experimental groups consisted of the following: (i) normal diet (ND, 18% kcal from fat), (ii) control HFD (CTL, 60% kcal from fat), (iii) HFD + PineXol (10 mg/kg BW, PX10), and (iv) HFD + PineXol (50 mg/kg BW, PX50). Food and water were fed ad libitum for 12 weeks, during which PineXol was administrated daily by oral gavage. The BW and food intake were measured weekly. Mice were sacrificed after 12 weeks. Blood was withdrawn from the retro-orbital cavity, and serum was collected by centrifugation at 2,000 ×g for 15 min at 4°C. Liver samples were collected and snap frozen, followed by storage at -80°C for further analysis.
Body Composition Assessment Using Dual-Energy X-Ray Absorptiometry (DEXA) Animals were fasted overnight for DEXA imaging and then intraperitoneally injected with ketamine (100 mg/kg BW) and xylazine (10 mg/kg BW) for anesthesia. The BW, lean body mass, body fat mass, and body fat percentage were measured at 0, 4, 8, and 12 weeks by an InAlyzer (Medikors, Korea).
Hepatic Triglyceride (TG) Synthesis Using Poloxamer 407 (P407) Mice were fasted for 4 h prior to the analysis of hepatic TG synthesis. P407, a lipoprotein lipase inhibitor, was purchased from Sigma Aldrich (USA). Animals were intraperitoneally injected with P407 at 1 g/kg BW to observe hepatic TG production. Serum was collected 0, 1, 2, 4, and 24 h after injection. Serum levels of TG at each time point were measured using a commercial kit (Wako, Ltd., Japan) [26] .
Blood Biomarker Assay
Serum levels of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) were assessed with a commercial kit (Asan Co., Korea) to determine liver function [27] . Levels of TG, total cholesterol (TC), and LDL cholesterol (LDL-C) were evaluated using a commercial kit (Wako Ltd.) [28] .
mRNA Expression Analysis
Total RNA was extracted from animal tissues using the Isol-RNA Lysis Reagent (5PRIME, USA), and 5 μg total RNA was reverse-transcribed into cDNA using the iScript Supermix (BioRad Co., USA). Twenty microliters of the total reaction volume, including cDNA, forward and reverse primers, and 10 μl iQ SYBR Green Supermix (Bio-Rad Co.), was used for real-time reversetranscription PCR (RT-PCR). Reactions were performed in duplicates with an 18S internal control. The cycle threshold value was utilized for quantification of mRNA expression levels.
Immunoblotting
Cytoplasmic proteins were prepared in 4× Laemmli sample buffer (Bio-Rad Co.) and 1× RIPA buffer (CellNest; Minato, Japan), containing a phosphatase inhibitor (Cell Signaling, USA) and a protease inhibitor (Cell Signaling). Lysates were subjected to 20% SDS-PAGE and transferred to a PVDF membrane. The membrane was blocked with 5% bovine serum albumin (GenDEPOT, Inc., USA) and immunoblotted using primary antibodies. Suitable HRP-conjugated secondary antibodies were applied, and the blots were quantified by Image Lab (Bio-Rad Co.). Antibodies to acetyl CoA carboxylase 1 (ACC1), fatty acid synthase (FAS), stearoyl CoA desaturase 1 (SCD1), CCAAT/enhancer-binding protein alpha (C/EBPα), peroxisome proliferator-activated receptor gamma (PPARγ), perilipin, and β-actin were purchased from Cell Signaling. Antibodies to microsomal TG transfer protein (MTP), elongase of very long chain fatty acids 6 (ELOVL6), and sterol regulatory element-binding protein 1 (SREBP1) were purchased from Santa Cruz Biotechnology (USA).
Statistical Analysis
All values are presented as the mean ± standard error. The statistical analysis was performed using Prism 6 (GraghPad Software, USA). Mouse growth performance (BW, feed intake, and fat mass) and hepatic TG synthesis were analyzed using a two-way analysis of variance (ANOVA). Other data were analyzed using a one-way ANOVA. A Dunnett's multiple comparisons test was used to compare means between the CTL, PX10, and PX50 groups, excluding the ND group. P values less than 0.05 were considered statistically significant.
Results
Effects of PineXol on Mouse Growth Performance and Body Composition
The BW and body composition were measured for 12 weeks, as shown in Fig. 1 . There were no differences in BW between the CTL and PX10 groups during the study period. The BW in the PX50 group was statistically lower than that in the CTL group from nine weeks to the end of the dietary intervention (p < 0.05) (Fig. 1A) . DEXA results include lean body mass, fat in the tissue, and X-ray image of mice. The lean body mass did not differ among the groups (Fig. 1B) . Strikingly, the PX50 group showed significantly lower body fat at 12 weeks compared with the CTL group (p < 0.001). Body fat in the CTL and PX10 groups was not significantly different at 12 weeks (Fig. 1C) . X-ray images show the fat distribution in red. In the PX50 group, the fat distribution was dramatically decreased compared with the CTL group (Fig. 1D) . BW gain, food intake, and animal food efficiency ratios are shown in Table 1 . None of these values of the PineXol-treated groups were significantly different from those of the CTL group. These results suggest that oral administration of PineXol does not induce a loss of appetite or an increase in food intake.
Effects of PineXol on Hepatic Function in Mice
Serum AST and ALT activities are shown in Table 2 as an analysis of liver function. There were no significant differences in AST values between the CTL and PineXoltreated groups. ALT values in the PineXol-treated groups were increased compared with those of the CTL group (p < 0.01). However, the ALT and AST values of all groups stayed within normal limits (0-40 IU/l). In addition, the AST/ALT ratio was used as an indicator of a functional liver disorder; this ratio was within the normal range (>1) in all groups, with no significant differences among them.
Effects of PineXol on Serum Lipid Profiles in Mice
Serum lipid profiles are shown in Fig. 2 . There were no significant differences in serum levels of TG at 12 weeks between any groups ( Fig. 2A) . Serum levels of TC in the PX50 group were approximately 25% lower than that of the CTL group (p < 0.01) (Fig. 2B) . Serum levels of LDL-C were significantly decreased in both the PX10 and PX50 groups by 25% compared with the CTL group (p < 0.01) (Fig. 2C) . Fig. 3 shows hepatic production of TG after P407 injection, an inhibitor of lipoprotein lipase. Initial TG production was not significantly different between any of the groups. TG production in the PX50 group was suppressed by approximately 40% compared with the CTL group at 24 h (p < 0.001). On the other hand, the PX10 group produced appoximately 17% more TG at 24 h compared with the CTL group (p < 0.001). Food efficiency ratio (FER) = (weight gain/food intake) × 100.
Effects of PineXol on Hepatic TG Production in Mice
Values are expressed as the mean ± standard error (n = 12). ALT, alanine aminotransferase; AST, aspartate aminotransferase. **p < 0.01; ***p < 0.001 compared with CTL. Values are expressed as the mean ± standard error (n = 4, sera were pooled).
Fig. 2. Effects of PineXol on serum lipid profiles in mice.
(A) Serum triglyceride, (B) serum total cholesterol, and (C) serum LDL-cholesterol levels. ND, normal diet; CTL, high-fat diet (HFD, 60% kcal from fat); PX10, HFD with PX 10 mg/kg/day; PX50, HFD with PX 50 mg/kg/day.**p < 0.01; ***p < 0.001. Data represent the mean ± standard error (n = 8).
Effects of PineXol on De Novo Lipogenesis in the Liver
In Fig. 4 , protein levels of ACC1, FAS, SCD1, ELOVL6, and MTP, which are the regulatory enzymes of de novo lipogenesis and adipogenesis, were examined by western blotting. SREBP1, a transcriptional regulatory factor, was also investigated. Expression levels were normalized to that of β-actin. Levels of ACC1, which synthesizes malonyl CoA, were decreased by 61% in the PX50 group compared with the CTL group (p < 0.01). Levels of SCD1, which desaturates fatty acids, were diminished by 40% in the PX50 group compared with the CTL group (p < 0.05). Levels of ELOVL6, which converts palmitic acid into stearic acid, were decreased by 56% in the PX50 group compared with the CTL group (p < 0.05). Levels of MTP, which transports TG in the plasma, were reduced by 74% in the PX50 group compared with the CTL group (p < 0.001). Levels of SREBP1, which stimulates regulatory enzymes for de novo lipogenesis, declined by 64% compared with the CTL group (p < 0.01). To summarize, the expression of each protein examined, except for FAS (which synthesizes palmitic acid from malonyl CoA), decreased considerably in the PX50 group compared with the CTL group. There were no significant differences in protein levels between the PX10 and CTL groups; additionally, mRNA expression levels were not significantly different between the CTL and PineXol-treated groups (data not shown).
Effects of PineXol on Adipogenesis in Mouse White
Adipose Tissue C/EBPα, PPARγ, and perilipin, which function in adipocyte differentiation in the white adipose tissue, were analyzed, and the results are shown in Fig. 5 . C/EBPα, a transcriptional factor, enhances early cellular differentiation, whereas PPARγ is preferentially expressed in adipocytes to stimulate adipogenesis. Perilipin serves as a protective coating against lipases and is localized at the periphery of lipid droplets. These factors were analyzed by RT-PCR and western blotting. Expression levels were normalized to that The relative intensities by densitometry are shown. Expression levels were normalized to that of β-actin. ND, normal diet; CTL, high-fat diet (HFD, 60% kcal from fat); PX10, HFD with PX 10 mg/kg/day; PX50, HFD with PX 50 mg/kg/day. *p < 0.05; **p < 0.01; ***p < 0.001. Data represent the mean ± standard error (n = 3). ACC1, acetyl-CoA carboxylase1; FAS, fatty acid synthase; SCD1, stearoyl-CoA desaturase 1; ELOVL6, elongase of very long chain fatty acids 6; MTP, microsomal triglyceride transfer protein; SREBP1, sterol regulatory element-binding protein 1.
of β-actin. Reduced mRNA expression levels of C/EBPα and PPARγ were observed in the PX50 group compared with the CTL group (p < 0.01 and p < 0.001, respectively). Levels of PPARγ were significantly decreased by 65% in the PX10 group compared with the CTL group (p < 0.01) (Fig. 5A) . These findings are consistent with the inhibition of protein expression. Protein levels of C/EBPα and PPARγ were clearly decreased in the PX50 group compared with the CTL group (p < 0.01 and p < 0.05, respectively). Levels of perilipin in the PineXol-treated groups were also significantly lower (approximately 80%) than that in the CTL group (p < 0.01) (Fig. 5B) .
Discussion
The composition of PineXol is similar to that of Pycnogenol. The main components of both are phenolic compounds and flavonoids [24, 25] . Pycnogenol and PineXol have been reported to possess comparable antioxidant effects [29] . However, the role of PineXol in obesity or lipid homeostasis is unclear. The degree of BW and body fat are generally used to define obesity. These values were both significantly decreased in the PX50 group compared with the CTL group. Likewise, BW and body fat mass were reduced significantly after nine weeks of 30 mg/kg Pycnogenol administration in C57BL/6J ob/ob mice [21] . Hsu and Yen [30] discovered that the phenolic compounds in Pycnogenol decreased the BW in mice fed a HFD. Sato et al. [31] established that the BW and white adipose tissue weight were remarkably diminished in ApoE
mice fed a pine bark extract for 9 weeks. Thus, PineXol supplementation in vivo reduces both BW and body fat mass.
Increased levels of serum ALT and AST are indicators of hepatic damage. Levels of ALT in PineXol-supplemented groups were significantly higher than those in the CTL group. However, these levels were all within the normal range (0-40 IU/l) [32] . Trevaskis et al. [33] reported ALT levels of 18 U/l in wild-type C57BL/6 mice and greater than 500 U/l in Lep Expression levels were normalized to that of β-actin. ND, normal diet; CTL, high-fat diet (HFD, 60% kcal from fat); PX10, HFD with PX 10 mg/kg/day; PX50, HFD with PX 50 mg/kg/day. *p < 0.05; **p < 0.01; ***p < 0.001. Data represent the mean ± standard error (n = 6). C/EBPα, CCAAT/enhancer-binding protein alpha; PPARγ, peroxisome proliferator-activated receptor gamma.
which liver injury was induced by polyinosinic:polycytidylic acid treatment. The AST/ALT ratio is known to be associated with functional liver impairment [35] ; there were no significant differences in the AST/ALT ratio between any groups examined in this study. Therefore, PineXol supplementation did not cause significant liver damage.
Blood lipid profiles, including TG, TC, and LDL-C, are widely used to diagnose the metabolic syndrome. The current study showed that serum levels of TC and LDL-C were significantly decreased in the PineXol-treated groups. A reduction in LDL-C is known to help prevent cardiovascular disease (CVD). Sato et al. [31] showed that serum and liver levels of TC, but not serum levels of TG, were dramatically lowered in pine bark extract-fed ApoE − / − mice after 9 weeks. Devaraj et al. [36] reported that Pycnogenol supplementation (150 mg/day) reduced plasma levels of LDL-C in healthy humans after 6 weeks. Furthermore, after 1 month, Pycnogenol supplementation (360 mg/day) significantly reduced serum levels of TC and LDL-C in 40 patients diagnosed with chronic venous insufficiency [37] . Therefore, PineXol would likely help prevent CVD in both mice and humans by improving levels of cholesterol. Hepatic TG production was significantly inhibited in the PX50 group but not in the PX10 group. These results are consistent with the levels of lipogenic enzymes present in the liver as determined by western blotting. Expression levels of ACC, SCD1, ELOVL6, MTP, and SREBP1 were lower in the PineXol-treated groups than in the CTL group, suggesting an anti-obesity effect via the down-regulation of de novo lipogenesis. Guerrero et al. [38] studied the effects of Pycnogenol on de novo lipid synthesis in HepG2 cells (hepatic human cells), finding that at a dose of 25 mg/l, Pycnogenol caused a significant reduction in cellular lipid levels. Taken together, PineXol may decrease de novo lipogenesis both in vivo and in vitro; however, additional studies must be performed to confirm these results.
In addition, we analyzed several enzymes present in the adipose tissue. Levels of C/EBPα, PPARγ, and perilipin were clearly suppressed in the PineXol-treated groups, suggesting that PineXol could be used to prevent obesity. Previous studies have reported similar antilipogenic effects in vitro: PineXol and Pycnogenol, for example, both inhibit lipid accumulation in 3T3-L1 adipocytes [16, 23] . Pycnogenol decreases the levels of perilipin A and H89 (a PKA inhibitor) in both ob/ob mice and primary adipocytes [21] . Yang et al. [39] also reported that Pycnogenol inhibited adipogenesis in 3T3-L1 cells via the suppression of PPARγ and adiponectin. Therefore, PineXol could block both adipogenesis and adipocyte differentiation.
In conclusion, PineXol supplementation in vivo downregulates hepatic de novo lipogenesis and inhibits adipogenesis in body fat. PineXol also improves levels of TC and LDL-C, thereby reducing BW and adiposity. These findings suggest that PineXol has the potential to improve conditions of hypercholesterolemia and obesity.
